ClinicalTrials.Veeva

Menu
I

IC La Serena Research | La Serena, Chile

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Nemtabrutinib
Gemcitabine
MK-7902
Cisplatin
MK-6482
Vericiguat
MK-1242-035
ACE-536
Bomedemstat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 21 total trials

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic c...

Active, not recruiting
Colorectal Cancer
Drug: regorafenib
Biological: favezelimab/pembrolizumab

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in partici...

Enrolling
CLL
Small-Cell Lymphoma
Drug: Nemtabrutinib
Biological: Rituximab

Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are typ...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Bendamustine
Drug: Cyclophosphamide

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenv...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab/Quavonlimab

This study is to assess the pharmacokinetics (PK) and safety of SC MK-3475A vs intravenous (IV) pembrolizumab, administered with chemotherapy in firs...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Biological: Pembrolizumab
Drug: Nab-paclitaxel

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fract...

Active, not recruiting
Chronic Heart Failure With Reduced Ejection Fraction
Drug: Vericiguat
Drug: Placebo

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with sel...

Enrolling
Follicular Lymphoma
Mantle Cell Lymphoma
Biological: Zilovertamab vedotin
Drug: Nemtabrutinib

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo
Locations recently updated

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head...

Enrolling
Recurrent or Metastatic Solid Tumors
Drug: Ifinatamab deruxtecan

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Active, not recruiting
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536
Locations recently updated

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential th...

Enrolling
Essential Thrombocythemia
Drug: Bomedemstat
Drug: Hydroxyurea
Status recently updated

Researchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive.* Metastatic means can...

Enrolling
Active, not recruiting
Non-Small-Cell Lung Carcinoma
Lung Neoplasms
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: 5-FU
Biological: Lenvatinib

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypo...

Enrolling
Systemic Lupus Erythematosus
Biological: MK-6194
Biological: Placebo

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with adva...

Active, not recruiting
Biliary Tract Carcinoma
Biological: Pembrolizumab
Drug: Placebo

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after in...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metas...

Enrolling
Prostate Cancer Metastatic
Drug: Dexamethasone
Drug: Hydrocortisone
Locations recently updated

Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated befor...

Enrolling
Melanoma
Drug: Lenvatinib
Biological: Vibostolimab

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Daiichi Sankyo logo
Merck KGaA (EMD Serono) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems